Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)

<h3>Purpose</h3><p dir="ltr">This systematic review and meta-analysis aims to evaluate the efficacy and safety of the combination of phenylephrine 1% and ketorolac 0.3% (OMIDRIA®) for optimizing pain management and maintaining pupil dilation during cataract surgery. Compa...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Mohamed Abo Zeid (20020680) (author)
مؤلفون آخرون: Amr Elrosasy (20020683) (author), Kareem Khalefa (22466368) (author), Mohamed Elhadary (16329082) (author), Shrouk F. Mohamed (22466371) (author), Amr Elkelany (22466374) (author), Hashem Abu Serhan (15993651) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513534644191232
author Mohamed Abo Zeid (20020680)
author2 Amr Elrosasy (20020683)
Kareem Khalefa (22466368)
Mohamed Elhadary (16329082)
Shrouk F. Mohamed (22466371)
Amr Elkelany (22466374)
Hashem Abu Serhan (15993651)
author2_role author
author
author
author
author
author
author_facet Mohamed Abo Zeid (20020680)
Amr Elrosasy (20020683)
Kareem Khalefa (22466368)
Mohamed Elhadary (16329082)
Shrouk F. Mohamed (22466371)
Amr Elkelany (22466374)
Hashem Abu Serhan (15993651)
author_role author
dc.creator.none.fl_str_mv Mohamed Abo Zeid (20020680)
Amr Elrosasy (20020683)
Kareem Khalefa (22466368)
Mohamed Elhadary (16329082)
Shrouk F. Mohamed (22466371)
Amr Elkelany (22466374)
Hashem Abu Serhan (15993651)
dc.date.none.fl_str_mv 2025-03-29T09:00:00Z
dc.identifier.none.fl_str_mv 10.1007/s00417-025-06811-y
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Optimizing_pain_management_and_pupil_dilation_in_cataract_surgery_a_systematic_review_and_meta-analysis_of_phenylephrine_ketorolac_OMIDRIA_/30405355
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Clinical sciences
Cataract surgery
Ketorolac
Phenylephrine
Postoperative pain
Pupil dilation
dc.title.none.fl_str_mv Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Purpose</h3><p dir="ltr">This systematic review and meta-analysis aims to evaluate the efficacy and safety of the combination of phenylephrine 1% and ketorolac 0.3% (OMIDRIA®) for optimizing pain management and maintaining pupil dilation during cataract surgery. Comparisons were made against placebo/vehicle, phenylephrine alone, and epinephrine.</p><h3>Methods</h3><p dir="ltr">A comprehensive search of PubMed, Cochrane CENTRAL, Embase, Scopus, and Web of Science was conducted. Eligible studies were randomized clinical trials and observational studies assessing intracameral phenylephrine/ketorolac against control groups. Key outcomes included pain management, pupil diameter, and adverse events. Data were synthesized using meta-analysis with fixed and random-effects models, and heterogeneity was assessed using the I<sup>2</sup> statistic.</p><h3>Results</h3><p dir="ltr">Ten studies, including 220,061 patients, were analyzed. The combination of phenylephrine/ketorolac significantly reduced postoperative pain (RR = 0.72, 95% CI: 0.60–0.86) and opioid use (RR = 0.45, 95% CI: 0.23–0.89) compared to vehicle and epinephrine. PE/K also maintained a larger pupil diameter (MD = 0.54 mm, 95% CI: 0.32–0.75) with minimal heterogeneity (I<sup>2</sup> = 0%) and reduced the incidence of severe pain (RR = 0.41, 95% CI: 0.27–0.63). No significant differences in adverse events such as elevated intraocular pressure, inflammation, or headaches were observed.</p><h3>Conclusion</h3><p dir="ltr">Phenylephrine/ketorolac (OMIDRIA®) demonstrates superior efficacy in maintaining intraoperative mydriasis, reducing postoperative pain, and minimizing opioid use without increasing adverse events. This combination offers a preferable alternative to traditional agents, potentially setting a new standard for pain management and pupil dilation in cataract surgery.</p><h2>Other Information</h2><p dir="ltr">Published in: Graefe's Archive for Clinical and Experimental Ophthalmology<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s00417-025-06811-y" target="_blank">https://dx.doi.org/10.1007/s00417-025-06811-y</a></p>
eu_rights_str_mv openAccess
id Manara2_084926ac9b4d4bf1344a75e866a7b076
identifier_str_mv 10.1007/s00417-025-06811-y
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/30405355
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)Mohamed Abo Zeid (20020680)Amr Elrosasy (20020683)Kareem Khalefa (22466368)Mohamed Elhadary (16329082)Shrouk F. Mohamed (22466371)Amr Elkelany (22466374)Hashem Abu Serhan (15993651)Biomedical and clinical sciencesClinical sciencesCataract surgeryKetorolacPhenylephrinePostoperative painPupil dilation<h3>Purpose</h3><p dir="ltr">This systematic review and meta-analysis aims to evaluate the efficacy and safety of the combination of phenylephrine 1% and ketorolac 0.3% (OMIDRIA®) for optimizing pain management and maintaining pupil dilation during cataract surgery. Comparisons were made against placebo/vehicle, phenylephrine alone, and epinephrine.</p><h3>Methods</h3><p dir="ltr">A comprehensive search of PubMed, Cochrane CENTRAL, Embase, Scopus, and Web of Science was conducted. Eligible studies were randomized clinical trials and observational studies assessing intracameral phenylephrine/ketorolac against control groups. Key outcomes included pain management, pupil diameter, and adverse events. Data were synthesized using meta-analysis with fixed and random-effects models, and heterogeneity was assessed using the I<sup>2</sup> statistic.</p><h3>Results</h3><p dir="ltr">Ten studies, including 220,061 patients, were analyzed. The combination of phenylephrine/ketorolac significantly reduced postoperative pain (RR = 0.72, 95% CI: 0.60–0.86) and opioid use (RR = 0.45, 95% CI: 0.23–0.89) compared to vehicle and epinephrine. PE/K also maintained a larger pupil diameter (MD = 0.54 mm, 95% CI: 0.32–0.75) with minimal heterogeneity (I<sup>2</sup> = 0%) and reduced the incidence of severe pain (RR = 0.41, 95% CI: 0.27–0.63). No significant differences in adverse events such as elevated intraocular pressure, inflammation, or headaches were observed.</p><h3>Conclusion</h3><p dir="ltr">Phenylephrine/ketorolac (OMIDRIA®) demonstrates superior efficacy in maintaining intraoperative mydriasis, reducing postoperative pain, and minimizing opioid use without increasing adverse events. This combination offers a preferable alternative to traditional agents, potentially setting a new standard for pain management and pupil dilation in cataract surgery.</p><h2>Other Information</h2><p dir="ltr">Published in: Graefe's Archive for Clinical and Experimental Ophthalmology<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s00417-025-06811-y" target="_blank">https://dx.doi.org/10.1007/s00417-025-06811-y</a></p>2025-03-29T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s00417-025-06811-yhttps://figshare.com/articles/journal_contribution/Optimizing_pain_management_and_pupil_dilation_in_cataract_surgery_a_systematic_review_and_meta-analysis_of_phenylephrine_ketorolac_OMIDRIA_/30405355CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304053552025-03-29T09:00:00Z
spellingShingle Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
Mohamed Abo Zeid (20020680)
Biomedical and clinical sciences
Clinical sciences
Cataract surgery
Ketorolac
Phenylephrine
Postoperative pain
Pupil dilation
status_str publishedVersion
title Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
title_full Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
title_fullStr Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
title_full_unstemmed Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
title_short Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
title_sort Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®)
topic Biomedical and clinical sciences
Clinical sciences
Cataract surgery
Ketorolac
Phenylephrine
Postoperative pain
Pupil dilation